USRE35724E - Contraception system and method - Google Patents

Contraception system and method Download PDF

Info

Publication number
USRE35724E
USRE35724E US08369309 US36930995A USRE35724E US RE35724 E USRE35724 E US RE35724E US 08369309 US08369309 US 08369309 US 36930995 A US36930995 A US 36930995A US RE35724 E USRE35724 E US RE35724E
Authority
US
Grant status
Grant
Patent type
Prior art keywords
progestin
estrogenic compound
follow
day
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08369309
Inventor
Samuel A. Pasquale
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone

Abstract

A method of contraception is disclosed which comprises a two-stage protocol. In the first stage, an estrogenic compound in a first composition is administered daily as the sole contraceptively active substance to a human female from about Day 2 to about Day 7 of her menstrual cycle, where Day 1 is the first day of menses. The second stage of the protocol occurs immediately thereafter during which at least one follow-up composition containing a progestin is administered daily to the same human female. The follow-up composition can contain a progestin as the sole contraceptively active ingredient, or can contain a combination of an estrogenic compound with a progestin in different weight ratios. A drug delivery system containing daily dosage units is also described.

Description

.Iadd.This is a continuation of application Ser. No. 07/875,277, filed Apr. 28, 1992. .Iaddend.

TECHNICAL FIELD

This invention relates to the practice of contraception utilizing a two-stage protocol that minimizes this incidence of breakthrough bleeding.

Background of the Invention

Oral contraceptives first became available in the early 1960's. Through continued research, new lower-dose estrogen products of high effectiveness have been developed. The oral administration of combination-type preparations containing estrogens and progestins has been known for some time. The administration of purely sequential preparations to mimic the normal 28-day menstrual cycle of the patient is also known. In such instances, an estrogen is administered at a high dosage, in the absence of a progestin, over a period of fourteen to sixteen days, thereafter the estrogen is administered at the same high dosage in combination with a relatively high amount of progestin over a period of five to six days, and during the next seven to eight days there is no administration of estrogen or progestin. Physician's Desk Reference, 30th edition, pages 1026, 1127 and 1532, respectively (1976).

It has more recently been published in Goodman and Gilman, The Pharmacological Basis of Therapeutics, 7th edition, pages 1430-1436 (1985), that sequential combination administration includes the usage of an estrogen at a high dosage, in the absence of a progestin, over a period of seven days, thereafter the estrogen is administered at the same high dosage in combination with a relatively high amount of s progestin over a period of 15 days, and during the next six days there is no administration of estrogen or progestin.

In Vorys U.S. Pat. Nos. 4,292,315 and 4,372,951, various sequential and combination oral contraceptive delivery systems are disclosed. All of the systems described in the patents to Vorys comprise an early 7-day period in which no exogenous steroids are administered, followed by a 7-day period in which a pharmacologically low dose of an unopposed estrogen or progestin steroid is administered daily, followed by an arbitrary 14-day period in which various combinations of estrogen and progestin are administered daily in various pharmacological dosages. None of the systems described in Vorys utilize the administration of an unopposed estrogen during the initial seven days of the menstrual cycle.

Biphasic and triphasic oral contraceptive combinations have been described in Pasquale U.S. Pat. Nos. 4,530,839; 4,544,554; and 4,628,051. The described biphasic and triphasic oral contraceptive systems do not include the administration of an unopposed estrogenic compound during the first seven days of the menstrual cycle. In the biphasic combination type oral contraceptives, a combination of an estrogen and a low dosage of a progestin is first administered for 10-12 days, Subsequently, a combination of the same dosage of estrogen and an increased progestin dosage is administered for the remaining 9-11 days of a 21-day regimen. The biphasic systems were developed in an effort to reduce dosage and keep bleeding patterns at an acceptable level.

In the triphasic oral contraceptive regimen, an estrogen dosage is kept constant throughout the 21-day regimen while the progestin dosage is gradually increased is successive steps. Thus, the 21-day regimen comprises an initial 7-day period in which a daily dose of a combination of an estrogenic compound together with a low dosage of a progestin is administered; followed by a 7-day period in which a daily dosage of an estrogenic compound together with a moderate progestin dosage is administered; followed by a terminal 7-day period in which a daily dosage of an estrogenically effective compound together with a high dose of an progestin is administered to a human female. This regimen is then followed by a 7-day period in which no hormone is given.

A disadvantage of the above-described oral contraceptive systems is that there often occurs an incidence of breakthrough bleeding and spotting. Additionally, there is a risk of escaped ovulation or pregnancy, especially if a daily tablet is missed during the cycle. Chowdhury et al., Contraception, 22:241-247 (1980); Molloy et al., Brit. Med. J. 290:1474-1473 (1985).

SUMMARY OF THE INVENTION

The present invention relates to a two-stage oral contraceptive system in which an unopposed estrogenic compound is administered during a terminal portion of the first 7-day segment of the menstrual cycle, counting as Day 1 the onset of menses. In the contemplated method aspect, an initial composition containing an estrogenic compound as the sole contraceptively active ingredient is administered during the terminal portion of the first 7-day segment of the menstrual cycle, preferably from about Day 2 to about Day 7, inclusive, of the menstrual cycle, at a daily dosage equivalent in estrogenic activity to about 0.01 to about 0.04 mg of 17-alpha-ethinyl estradiol, to a human female of child-bearing age for contraception purposes. Following this initial administration of a relatively small dosage of an unopposed estrogenic compound, the second stage of the contemplated contraceptive system is commenced. In the second stage, a daily administration of a follow-up composition containing a progestin, alone or in combination with an estrogenic compound, is continued to about Day 28 of the menstrual cycle.

The method of contraception of the present invention contemplates that the follow-up composition, administered during Days 7 to 28 of the menstrual cycle preferably contains a combination of an estrogenic compound and a progestin. The composition administered during the second stage can be a uniphasic, biphasic or triphasic combination oral contraceptive system.

In the present drug delivery system at least 24 separate dosage units are included for successive daily oral administration. Preferably, at least three initial dosage units contain a pharmacologically active daily dosage amount of an unopposed estrogenic compound, and the remainder each contain a pharmacologically active daily dosage amount of a composition containing a progestin as aforesaid.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention provides a two-stage protocol which is utilized as a method of contraception in a human Female while minimizing the incidence of breakthrough bleeding. In the first stage of this protocol, a composition containing an estrogenic compound as the sole contraceptively active ingredient is administered during a terminal portion of the first 7-day segment of the menstrual cycle, preferably from Day 4 to Day 7 of the menstrual cycle. In the second stage of the protocol commencing immediately after the first stage, a follow-up daily dosage of a composition containing a progestin is administered through Day 28 of the menstrual cycle. Throughout the present specification and claims, Day 1 of the menstrual cycle is defined as the day on which onset of menses is noted.

This follow-up progestin-containing composition can be:

(1) a composition containing an unopposed progestin;

(2) a combination of an estrogenic compound and a progestin;

(3) a biphasic oral contraceptive in which one dosage of a combination of an estrogenic compound and a progestin is administered daily for about 10 days of the menstrual cycle, and followed by administration of a follow-up dosage of an estrogenic compound and a progestin, which is administered daily for the remainder of the menstrual cycle; or

(4) a triphasic oral contraceptive, in which three group of seven daily dosages each, are administered consecutively in a predetermined sequence. The dosage units in each such group contain a composition of an estrogenic compound and a progestin; however all three groups do not contain the same weight ratio of estrogenic compound and progestin.

Estrogenic compounds, as the term is used herein, includes hormones as well as other compounds that exhibit estrogenic activity. That is, an estrogenic compound is a compound having the ability to elicit a physiological response similar to that normally produced by endogenous estrogen in a human female, such as inhibition of follicle stimulating hormone (FSH) secretion. Illustrative such compounds include 17-alpha-ethinyl estradiol 3-methylether, mestranol, 17-beta-estradiol, 17-alpha-ethinyl estradiol, and the like.

Progestins utilizable in the present invention include progestrone and its derivatives such as, for example, 17-hydroxy progestrone esters and 19-nor-17-hydroxy progestrone esters, 17-alpha-ethinyl testosterone, 17-alpha-ethinyl-19-nortestosterone and derivatives thereof, norethindrone, norgestrel, norgestamate. Desorgestrel, and D-17-beta-acetoxy-17-beta-ethyl17-alpha-ethinyl-gon-4-en-3-one oxime. The preferred progestins are norethindrone, D-norgestrel and D-17-beta-acetoxy-13-beta-ethyl-17-alpha-ethinyl-gon-4-en-3-one oxime.

A preferred dosage of an estrogenic compound in the present invention is a dosage that is equivalent in estrogenic activity to about 0.01 to about 0.04 milligrams (mg) of 17-alpha-ethinyl estradiol.

Preferred dosages for the progestin of the present invention are about 0.5 to about 1.0 mg.

In spontaneous menstrual cycles, the dominant follicle is recruited during the first six days of the menstrual cycle, where Day 1 is counted as the first day of bleeding. During this period of time, the FSH level is slightly elevated, and then decreases to peak again at mid-cycle at the time of ovulation. The present invention utilizes the fact that estrogen suppresses FSH levels. Thus, by administration of estrogen during the first seven days of the menstrual cycle, the follicular period, escape ovulation is less likely to occur if a dosage unit is missed.

Estrogen administration at this early stage of the menstrual cycle also prevents recruitment of the dominant follicle and thus allows a reduction in the dose of the estrogen and progestin in the combination oral contraceptive needed between Days 7 and 28 of the menstrual cycle to prevent conception. Additionally, estrogens stimulate progesterone receptor sites. By simulation of progesterone receptors early in the menstrual cycle, estrogen administration allows a reduction in the incidence of intermenstrual bleeding. That is, breakthrough bleeding and spotting are minimized with the low-dose oral contraceptives of the present invention.

Following the period of unopposed estrogen administration during the follicular period of the menstrual cycle, a second stage of administration comprising a 21-day regime of daily dosages of a standard oral contraceptive composition is followed. This second stage period comprises the administration of successive daily dosages of a progestin-containing composition.

Illustrative of the second stage of the method of the present invention are oral contraceptive compositions which contain one or more combination dosages of an estrogenic compound and a progestin, or a progestin alone. Such following-up combinations of an estrogenic compound and a progestin can constitute a uniphasic, biphasic or triphasic oral contraceptive system.

In the uniphasic system, a single dosage of a combination of an estrogenic compound and a progestin is administered daily for the 21 days of the second stage of the method of the present invention. In a preferred uniphasic system, a daily dosage unit containing 0.035 mg ethinyl estradiol and 0.5 mg norethindrone is administered.

In the biphasic system, two different dosage levels of an estrogenic compound and a progestin are administered, one level for about 7 to about 10 days of the 21-day regimen and the second dosage level for the remainder of the menstrual cycle.

In one preferred system, plural follow-up compositions are administered in sequence. The daily dosage of the estrogenic compound is substantially the same in all administered follow-up compositions, and the daily dosage of the progestin is greater in each successive follow-up composition. In a particularly preferred embodiment, a daily dosage of 0.035 mg ethinyl estradiol and 0.5 mg of norethindrone is administered to a female for about 7 to about 10 days, followed immediately in sequence by a daily dosage of 0.035 mg ethinyl estradiol and 1.0 mg norethindrone for the remainder of the menstrual cycle.

In the triphasic system, administration is divided into three approximately 7-day periods of daily oral contraceptive administration; the daily dosage level of the combination of an estrogenic compound and a progestin varies between successive approximately 7-day regimen periods. In the triphasic system, the three respective dosages can be different from each other or can be similar to each other during the first and third 7-day periods of administration.

In a particularly preferred embodiments, a daily dosage of 0.035 mg ethinyl estradiol and 0.5 mg norethindrone is administered to a female for about seven days, followed immediately in sequence by the daily administration of 0.035 mg ethinyl estradiol and 0.75 mg norethindrone for the next seven days, and then followed immediately in sequence by the daily administration of 0.035 mg ethinyl estradiol and 1.0 mg norethindrone for the remaining seven days of the menstrual cycle.

In a second preferred system of contraception, plural follow-up compositions are administered in sequence in which the daily dosage of the estrogenic compound is substantially the same in all administered follow-up compositions and in which the daily dosage of progestin in successive follow-up compositions first increases to a value greater than the level of progestin first administered and then decreases to a level corresponding to the same value as that of the progestin first administered as the daily progestin dosage. In a particularly preferred embodiment, a daily dosage of 0.035 mg ethinyl estradiol and 0.5 mg norethindrone is administered for about seven days, immediately followed by a daily administration of a dosage of 0.035 mg ethinyl estradiol and 1.0 mg norethindrone for about the next seven days, and then immediately followed by a daily administration of a dosage of 0.035 mg ethinyl estradiol and 0.5 mg norethindrone for the remaining seven days of the menstrual cycle.

The estrogen and progestin components in the second stage of the present invention are preferably administered admixed together, but they can also be administered separately. In general, the effective agents are compounded together to form a single dosage unit. Preferred dosage units are tablets or pills.

In the dosage units, the effective contraceptive agents are combined with the excipients, vehicles, and pharmacologically acceptable carriers commonly employed by one of ordinary skill in the preparation of pharmaceuticals in accordance with generally accepted pharmaceutical practices. Exemplary pharmaceutically acceptable carriers include corn starch, lactose, dicalcium phosphate, thickeners such as tragacanth and methylcellulose U. S. P., Freely divided SiO2, polyvinylpyrrolidone, magnesium stearate and the like. Additionally, a solid carrier can include biodegradable and non-biodegradable polymers and polypeptide carriers. Antioxidants, such as methylparaben and propylparaben can be present, as can sweeteners such as cane or beet sugar, sodium saccharin, sodium cyclamate and the dipeptide methylester sweeteners commercially available under the trademark NUTRA SWEET (aspartame) by the Nutrasweet Company (North Chicago, Ill.). Among the various oral dosage forms, tablets, capsules, and pills are particularly preferred.

A drug delivery system embodying the present invention contains a pharmaceutical package having at least 24 active dosage units arranged sequentially therein. Preferably, the pharmaceutical package contains 28 dosage units, including placebo units. This drug delivery system has at least four dosage units for the first stage of the method of the present invention and 21 dosage units for the second stage thereof. A single dosage unit is a daily dosage unit to be taken each day over the period of administration.

In a particularly preferred embodiment, the drug delivery system of the present invention contains 28 tablets. The first set of tablets in each sequence contains a placebo, the next four or five tablets in the sequence contain a composition of an unopposed estrogenic compound, and the remaining 21 tablets in the sequence contain a desired follow-up oral contraceptive composition as described hereinabove.

In a preferred embodiment the twenty one follow-up dosage units each contain substantially the same daily dosage of an estrogenic compound and a progestin.

In an alternate preferred embodiment the twenty one follow-up dosage units comprise a first group of 10 dosage units that each contain a first contraceptively effective daily dosage of an estrogenic compound and a progestin, and a second group of 11 dosage units that each contain a second follow-up contraceptively effective dosage of a progestin and an estrogenic compound.

In another alternate preferred embodiment, the twenty-one follow-up dosage units comprise three consecutive groups of about seven dosage units each, where each group contains contraceptively effective daily dosage units of an estrogenic compound and a progestin. The estrogenic compound and progestin in each individual group are present in substantially the same weight ratio, with the proviso that the weight ratios of the estrogenic compound to the progestin are different for the respective dosage units that constitute consecutively administered groups.

Certain specific examples are provided hereinbelow for purposes of illustration only and are not to be taken as limiting.

EXAMPLE 1 Estrongenic Compound Plus Uniphasic Contraceptive Regimen

A placebo tablet is administered to a menstruating human female for the first two days of the menstrual cycle, at Day 1 is the first day of bleeding. On Days 3 to 7, inclusive, 0.02 mg of ethinyl estradiol is administered daily. From Day 8 to the end of the menstrual cycle at Day 28, inclusive, a daily dosage of 0.035 mg of ethinyl estradiol together with 0.5 mg of norethindrone is administered. This regimen is illustrated in TABLE I.

              TABLE I______________________________________Contraceptive Regimen______________________________________Day       1       2     3     4   5     6   7Composition     P       P     E     E   E     E   EDay       8       9     10    11  12    13  14Composition     C       C     C     C   C     C   CDay       15      16    17    18  19    20  21Composition     C       C     C     C   C     C   CDay       22      23    24    25  26    27  28Composition     C       C     C     C   C     C   C______________________________________ Day = Day of the Menstrual Cycle: Day 1 as the first day of bleeding. Composition = the active ingredient(s) present in a daily dosage unit taken on the respective day of the menstrual cycle. P = placebo, contains no contraceptively active ingredients. E = 0.02 mg ethinyl estradiol. C = combination containing 0.035 mg ethinyl estradiol and 0.5 mg norethindrone.
EXAMPLE 2 Estrogenic Compound Plus Uniphasic Contraceptive Regimen

A placebo tablet is administered to a menstruating human female for the first two days of menstrual cycle, where Day 1 is the first day of bleeding. On Days 3 to 7, inclusive, 0.04 mg of ethinyl estradiol is administered daily. From Day 8 to the end of her menstrual cycle at Day 28, inclusive, a daily dosage of 0.035 mg ethinyl estradiol together with 0.5 mg norethindrone is administered. This regimen is illustrated in TABLE II.

              TABLE II______________________________________Contraceptive Regimen______________________________________Day       1       2     3     4   5     6   7Composition     P       P     E     E   E     E   EDay       8       9     10    11  12    13  14Composition     C       C     C     C   C     C   CDay       15      16    17    18  19    20  21Composition     C       C     C     C   C     C   CDay       22      23    24    25  26    27  28Composition     C       C     C     C   C     C   C______________________________________ Day = Day of the Menstrual Cycle: Day 1 is the first day of bleeding. Composition = the active ingredient(s) present in a daily dosage unit taken on the respective day of the menstrual cycle. P = placebo, contains no contraceptively active ingredient. E = 0.04 mg ethinyl estradiol. C = combination containing 0.035 mg ethinyl estradiol and 0.5 mg norethindrone.
EXAMPLE 3 Estrogenic Compound Plus Triphasic Contraceptive Regimen

A placebo dosage is administered to a menstruating human female for the first two days of her menstrual cycle, where Day 1 is the first day of bleeding. On Days 3 to 7, inclusive, a daily dosage of about 0.02 mg to about 0.04 mg of ethinyl estradiol is administered. From Day 8 to Day 14, inclusive, a daily dosage of 0.035 mg ethinyl estradiol together with 0.5 mg norethindrone is administered. From Day 15 to Day 21, inclusive, 0.035 mg of ethinyl estradiol together with 0.75 mg norethindrone is administered daily. Following this, a third phase is begun where from Day 22 to Day 28, inclusive, a daily dosage of 0.035 mg ethinyl estradiol together with 1.0 mg of norethindrone is administered. This regimen is illustrated in TABLE III.

              TABLE III______________________________________Contraceptive Regimen______________________________________Day       1       2     3     4   5     6   7Composition     P       P     E     E   E     E   EDay       8       9     10    11  12    13  14Composition     C1      C1    C1    C1  C1    C1  C1Day       15      16    17    18  19    20  21Composition     C2      C2    C2    C2  C2    C2  C2Day       22      23    24    25  26    27  28Composition     C3      C3    C3    C3  C3    C3  C3______________________________________ Day = Day of the Menstrual Cycle: Day 1 is the first day of bleeding. Composition = the active ingredient(s) present in a daily dosage unit taken on the respective day of the menstrual cycle. P = placebo, contains no contraceptively active ingredients. E = about 0.02 to about 0.04 mg ethenyl estradiol. C1 = 0.035 mg ethinyl estradiol and 0.5 mg norethindrone. C2 = 0.035 mg ethinyl estradiol and 0.75 mg norethindrone. C3 = 0.035 mg ethinyl estradiol and 1.0 mg norethindrone.

The foregoing specification, including the specific embodiment and examples, is intended to be illustrative of the present invention and is not to be takes as limiting. Numerous other variations and modifications can be effective without departing from true spirit and scope of the present invention.

Claims (28)

I claim:
1. A method of contraception .Iadd.by suppressing recruitment of the dominant follicle .Iaddend.comprising:
(a) administering .Iadd.orally .Iaddend.to a human female of child-bearing age, daily from . .about Day 2 to about.!. .Iadd.Day 3 or Day 4 through .Iaddend.Day 7 of her menstrual cycle, wherein Day 1 is the first day of menses, a first composition containing as sole contraceptively active ingredient an estrogenic compound at a daily dosage equivalent in estrogenic activity in the range of about 0.01 to about 0.04 milligrams of 17-alpha-ethinyl estradiol; and thereafter
(b) administering .Iadd.orally .Iaddend.to said female, daily through Day 28 of her menstrual cycle, at least one follow-up composition containing a contraceptively effective daily dosage of a progestin.
2. The method of contraception according to claim 1, wherein said follow-up composition contains a progestin as sole contraceptively active ingredient.
3. The method of contraception according to claim 1, wherein said follow-up composition comprises contraceptively effective amounts of an estrogenic compound and a progestin.
4. The method of contraception according to claim 1 wherein said estrogenic compound is ethinyl estradiol.
5. The method of contraception according to claim 1 wherein said estrogenic compound is mestranol.
6. The method of contraception according to claim 1 wherein said estrogenic compound is 17-beta-estradiol.
7. The method of contraception according to claim 1 wherein said follow-up composition contains norethindrone at a daily dosage in the range of about 0.5 mg to about 1.0 mg.
8. The method of contraception according to claim 1, wherein said progestin is D-norgestrel.
9. The method of contraception according to claim 1, wherein said progestin is D-17-beta-acetoxy-13-beta-ethyl-17-alpha-ethinyl-gon-4-en-3-one oxime.
10. The method of contraception according to claim 1, wherein said progestin is a 19-nor-17-hydroxy progesterone ester.
11. The method of contraception according to claim 1 wherein said estrogenic compound is ethinyl estradiol and said progestin is norethindrone.
12. The method of contraception according to claim 1 wherein said estrogenic compound is mestranol and said progestin is D-norgestrel.
13. The method of contraception according to claim 1 wherein plural follow-up compositions are administered in sequence, wherein the daily dosage of the estrogenic compound is substantially the same in all administered follow-up compositions, and wherein the daily dosage of progestin is greater in each successive follow-up composition.
14. The method of contraception according to claim 13 wherein said estrogenic compound is ethinyl estradiol and said progestin is norethindrone.
15. The method of contraception according to claim 14 wherein said daily dosage of ethinyl estradiol is about 0.035 mg.
16. The method of contraception according to claim 1 wherein plural follow-up compositions are administered in sequence, wherein the daily dosage of the estrogenic compound is substantially the same in all administered follow-up compositions; and wherein the daily dosage or progestin in successive follow-up compositions first increases to a value greater than the daily progestin dosage first administered and then decreases to the same value as the daily progestin dosage first administered.
17. The method of contraception according to claim 16 wherein said daily dosage of ethinyl estradiol is 0.035 mg.
18. A drug delivery system constituted by at least 24 separate daily dosage units, adapted for oral administration and comprising:
at least four .Iadd.but not more than five .Iaddend.initial dosage units each containing as the sole contraceptively active ingredient the same contraceptively effective daily dosage of an estrogenic compound;
followed by twenty-one follow-up dosage units each containing a contraceptively effective daily dosage of a progestin.
19. The drug delivery system according to claim 18, wherein aid twenty-one follow-up dosage units each contain substantially the same daily dosage of a progestin.
20. The drug delivery system according to claim 18, wherein said twenty-one follow-up dosage units each contain substantially the same daily dosage of an estrogenic compound and a progestin.
21. The drug delivery system according to claim 18 wherein said twenty-one follow-up dosage units comprise a first group of 10 dosage units that each contain a first contraceptively effective daily dosage of an estrogenic compound and a progestin, and a second group of 11 dosage units that each contain a follow-up contraceptively effective daily dosage of a progestin and an estrogenic compound.
22. The drug delivery system according to claim 18 wherein said follow-up dosage units comprise three consecutive groups of about seven dosage units each, and wherein each of said groups individually comprises contraceptively effective daily dosage units of an estrogenic compound and a progestin present in substantially the same weight ratio, with the proviso that the weight ratios of said estrogenic compound to said progestin are different for the respective dosage units that constitute consecutively administered groups.
23. The drug delivery system according to claim 22 wherein the weight ratio of said estrogenic compound to said progestin is substantially the same in the first and the third consecutive groups of dosage units.
24. The drug delivery system according to claim 18 wherein said estrogenic compound present in said initial dosage units is ethinyl estradiol.
25. The group delivery system according to claim 18 wherein said estrogenic compound present in said initial dosage units is mestranol.
26. The drug delivery system according to claim 18 wherein said estrogenic compound present in said initial dosage units is 17-beta-estradiol.
27. The drug delivery system according to claim 18, wherein said progestin is norethindrone.
28. The drug delivery system according to claim 18 wherein said progestin is D-norgestrel.
US08369309 1982-04-28 1995-01-06 Contraception system and method Expired - Lifetime USRE35724E (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US87527782 true 1982-04-28 1982-04-28
US07260447 US4921843A (en) 1988-10-20 1988-10-20 Contraception system and method
US08369309 USRE35724E (en) 1982-04-28 1995-01-06 Contraception system and method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08369309 USRE35724E (en) 1982-04-28 1995-01-06 Contraception system and method

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US87527782 Continuation 1982-04-28 1982-04-28
US07260447 Reissue US4921843A (en) 1988-10-20 1988-10-20 Contraception system and method

Publications (1)

Publication Number Publication Date
USRE35724E true USRE35724E (en) 1998-02-03

Family

ID=26947998

Family Applications (1)

Application Number Title Priority Date Filing Date
US08369309 Expired - Lifetime USRE35724E (en) 1982-04-28 1995-01-06 Contraception system and method

Country Status (1)

Country Link
US (1) USRE35724E (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US20030139381A1 (en) * 2001-12-05 2003-07-24 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20050143359A1 (en) * 2003-07-16 2005-06-30 Bell Robert G. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20070004690A1 (en) * 2005-06-29 2007-01-04 Boissonneault Roger M Quadraphasis continuous graduated estrogen contraceptive
US20070207945A1 (en) * 2006-03-02 2007-09-06 Warner Chilcott Company Inc. Extended cycle multiphasic oral contraceptive method
US20080125402A1 (en) * 2004-10-07 2008-05-29 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409721A (en) * 1967-09-15 1968-11-05 Neomed Lab Inc Oral dosage system effective to control the reproduction cycle
US3502772A (en) * 1966-11-02 1970-03-24 Organon Method for stimulating anovulatory cycles and pharmaceutical packages
US4372951A (en) * 1979-10-11 1983-02-08 Nichols Vorys Vaginal delivery for physiologic follicular-luteal steroid treatment
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4621079A (en) * 1983-12-22 1986-11-04 Schering Aktiengesellschaft Multistage combination preparation and its use for oral contraception
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3502772A (en) * 1966-11-02 1970-03-24 Organon Method for stimulating anovulatory cycles and pharmaceutical packages
US3409721A (en) * 1967-09-15 1968-11-05 Neomed Lab Inc Oral dosage system effective to control the reproduction cycle
US4372951A (en) * 1979-10-11 1983-02-08 Nichols Vorys Vaginal delivery for physiologic follicular-luteal steroid treatment
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4621079A (en) * 1983-12-22 1986-11-04 Schering Aktiengesellschaft Multistage combination preparation and its use for oral contraception

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Goodman and Gilman, "The Pharmacological Basis of Therapeutics", 7th ed. (1985), pp. 1430-1436.
Goodman and Gilman, The Pharmacological Basis of Therapeutics , 7th ed. (1985), pp. 1430 1436. *
Rote Liste, 1982, Abstract No. 75157. *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US20080132473A1 (en) * 2001-12-05 2008-06-05 Bell Robert G Oral Contraceptives to Prevent Pregnancy and Diminish Premenstrual Symptomatology
US20030139381A1 (en) * 2001-12-05 2003-07-24 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US8338396B2 (en) 2001-12-05 2012-12-25 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7858605B2 (en) * 2001-12-05 2010-12-28 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7320969B2 (en) 2001-12-05 2008-01-22 Duramed Pharmaceuticals, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7615545B2 (en) 2001-12-05 2009-11-10 Duramed Pharmaceuticals, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20100298279A1 (en) * 2001-12-05 2010-11-25 Bell Robert G Oral Contraceptives to Prevent Pregnancy and Diminish Premenstrual Symptomatology
US8680084B2 (en) 2001-12-05 2014-03-25 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20050143359A1 (en) * 2003-07-16 2005-06-30 Bell Robert G. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US7855190B2 (en) 2003-07-16 2010-12-21 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20110124611A1 (en) * 2003-07-16 2011-05-26 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US8415332B2 (en) 2004-10-07 2013-04-09 TEVA Woman's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20080125402A1 (en) * 2004-10-07 2008-05-29 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US8450299B2 (en) 2004-10-07 2013-05-28 Teva Womans's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20070004690A1 (en) * 2005-06-29 2007-01-04 Boissonneault Roger M Quadraphasis continuous graduated estrogen contraceptive
US8461138B2 (en) * 2005-06-29 2013-06-11 Warner Chilcott Company, Llc Quadraphasis continuous graduated estrogen contraceptive
US8063030B2 (en) * 2006-03-02 2011-11-22 Warner Chilcott Company, Llc Extended cycle multiphasic oral contraceptive method
US20070207945A1 (en) * 2006-03-02 2007-09-06 Warner Chilcott Company Inc. Extended cycle multiphasic oral contraceptive method

Similar Documents

Publication Publication Date Title
US3502772A (en) Method for stimulating anovulatory cycles and pharmaceutical packages
US3568828A (en) Modified sequential oral contraceptive
US5662927A (en) Method of hormonal contraception
US5043331A (en) Treatment of postmenopausal disorders
US4826831A (en) Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US3957982A (en) Method for contraception by the application of combination-type sequential preparations
US5468736A (en) Hormone replacement therapy
US4670426A (en) Interruption of fertility in mammals by post-coital pills
US3942641A (en) Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
US4378356A (en) Multi-phase combination-type sequential preparation for oral contraception and method of oral contraception
US4390531A (en) Method of contraception using peak progestogen dosage
US3932635A (en) Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
US5108995A (en) Hormone preparation and method
US5585370A (en) Hormone preparation and method
US5256421A (en) Hormone preparation and method
US6251956B1 (en) Combination progestin oral contraceptive regimen
US5418228A (en) Contraceptive regimen
US5858405A (en) Oral contraceptive
US5747480A (en) Oral contraceptive
US3836651A (en) Novel oral contraceptive combination
US5888543A (en) Oral contraceptives
US5280023A (en) Ovulation-inhibiting preparation for hormonal contraception
US4425339A (en) Treatment of menopausal symptoms
US6479475B1 (en) Oral contraceptive
US3230142A (en) Oral contraceptive compositions and methods

Legal Events

Date Code Title Description
AS Assignment

Owner name: BTG ACQUISITION SUBSIDIARY, INC., NEW JERSEY

Free format text: MERGER;ASSIGNOR:GYNEX PHARMACEUTICALS, INC.;REEL/FRAME:007769/0067

Effective date: 19930806

Owner name: BTG PHARMACEUTICALS CORP., NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:BTG ACQUISITION SUBSIDIARY, INC.;REEL/FRAME:007769/0073

Effective date: 19930806

AS Assignment

Owner name: BIO-TECHNOLOGY GENERAL CORP., NEW JERSEY

Free format text: MERGER;ASSIGNOR:BTG PHARMACEUTICALS CORPORATION;REEL/FRAME:008262/0685

Effective date: 19960314

PTEF Application for a patent term extension

Free format text: PRODUCT NAME: MIRCETTE (DESIGESTREL & ETHINYL ESTRADIOL); REQUESTED FOR 1028 DAYS; FAILURE TO COMPLY WITH 156(A)(5)(A) AND (D)(1) TIMELINESS REQUIREMENTS

Filing date: 19980622

Expiry date: 20081020

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: SAVIENT PHARMACEUTICALS, INC., NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:BIO-TECHNOLOGY GENERAL CORP.;REEL/FRAME:014871/0808

Effective date: 20030623

AS Assignment

Owner name: SAVIENT PHARMACEUTICALS, INC., NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:BIO-TECHNOLOGY GENERAL CORP.;REEL/FRAME:014754/0469

Effective date: 20030623

PTER Rejection of a request for patent term extension (for eg. ineligible, dismissal, withdrawal, etc)

Free format text: PRODUCT NAME: MIRCETTE (DESIGESTREL & ETHINYL ESTRADIOL)

Filing date: 19980622

Expiry date: 20081020

AS Assignment

Owner name: MORGAN STANLEY SENIOR FUNDING INC., NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNOR:SAVIENT PHARMACEUTICALS, INC.;REEL/FRAME:028363/0040

Effective date: 20120509

AS Assignment

Owner name: U.S. NATIONAL BANK ASSOCIATION, AS COLLATERAL AGEN

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 028363 FRAME 0040. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT;ASSIGNOR:SAVIENT PHARMACEUTICALS, INC.;REEL/FRAME:030936/0072

Effective date: 20120509